Across TCGA pan-cancer cohorts, FAM71A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM71A data layer compared with 11 for mass-spec protein and 9 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher FAM71A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM71A expression acts as an unfavorable survival marker.
GBM are the cancer types where FAM71A mass-spec protein most reproducibly stratifies survival.